Print this page
-
Phase 1/1b Study of AKT Inhibitor Ipatasertib with Chemoradiation for Locally Advanced Head and Neck Cancer.
Protocol: 032204Principal Investigator:
- Malcolm Mattes (New Jersey Medical School)
Applicable Disease Sites: Lip, Oral Cavity and Pharynx
Larynx -
Using Maackia Amurensis Seed Lectin to Target the Podoplanin Receptor as a Functionally Relevant Biomarker to Inhibit the Growth of Oral Squamous Cell Carcinoma and Precancerous Lesions.
Protocol: 032206Principal Investigator:
- Mahnaz Fatahzadeh DMD (Archived - Rutgers New Jersey Medical School)
Applicable Disease Sites: Lip, Oral Cavity and Pharynx -
A Phase II Trial of T Cell Receptor Gene Therapy Targeting HPV-16 E7 for HPV-Associated Cancers.
Protocol: 192204Principal Investigator:
- Christian Hinrichs (Rutgers University)
Applicable Disease Sites: Other Male Genital
Larynx
Other Female Genital
Cervix
Anus
Lip, Oral Cavity and Pharynx -
A Phase I Study to Evaluate the Safety of Colchicine for Treatment and Prevention of Radiation-Induced Dermatitis.
Protocol: 032112Principal Investigator:
- Bruce Haffty MD (Rutgers University)
Applicable Disease Sites: Lip, Oral Cavity and Pharynx -
Biomarkers of Oral Carcinogenesis and Oral Cancer Pain
Protocol: 032202Principal Investigator:
- Dylan Roden (New Jersey Medical School)
Applicable Disease Sites: Lip, Oral Cavity and Pharynx -
A Phase 2 Study Using Chemoimmunotherapy with Gemcitabine, Cisplatin and Nivolumab in Newly Diagnosed Nasopharyngeal Carcinoma (NPC).
Protocol: 112405Principal Investigator:
- Scott Moerdler M.D. (Rutgers University)
Applicable Disease Sites: Lip, Oral Cavity and Pharynx
- 1
- 2